Linsitinib (OSI-906)

製品コードS1091

Linsitinib (OSI-906)化学構造

分子量(MW):421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

サイズ 価格(税別)  
JPY 31540.00
JPY 28220.00
JPY 44820.00
JPY 119520.00

文献中Selleckの製品使用例(33)

カスタマーフィードバック(6)

  • (e) c-peptide from these mice 240 min after respective treatments.

    Nature, 2018, 560(7719):499-503. Linsitinib (OSI-906) purchased from Selleck.

    Inhibition of IGF receptor by the IGFR inhibitor linsitinib reduced ERK1/2 signaling activation particularly in U87MG RG7388 resistant cells.

    Clin Cancer Res, 2018, doi:10.1158/1078-0432.CCR-18-1580. Linsitinib (OSI-906) purchased from Selleck.

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

製品安全説明書

IGF-1R阻害剤の選択性比較

生物活性

製品説明 Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
ターゲット
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
体外試験

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk M{TmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\kTWM2OD1yLkCyPFA3KM7:TR?= MXXTRW5ITVJ?
KS-1 NFrt[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonyTWM2OD1yLkCzPFM2KM7:TR?= M3rHO3NCVkeHUh?=
TE-11 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTBwMEe4NlIh|ryP MlXuV2FPT0WU
EW-1 NH;jOmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\Q[2lEPTB;MD6wPFU5PSEQvF2= NFPkXmlUSU6JRWK=
HMV-II NYnYO2V3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rRXWlEPTB;MD6wPFg1PiEQvF2= MnHWV2FPT0WU
COLO-205 NHzPc5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnuwTWM2OD1yLkGwOFU1KM7:TR?= MYrTRW5ITVJ?
ES1 NXezVYlJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnLR2dKSzVyPUCuNVA3QTZizszN M4nITHNCVkeHUh?=
GDM-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nCbGlEPTB;MD6xN|Y4OiEQvF2= MnzEV2FPT0WU
ML-2 NITvcYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHJTWM2OD1yLkG1PFk3KM7:TR?= NHO1fVFUSU6JRWK=
Saos-2 MoG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInp[m9KSzVyPUCuNVY2OjZizszN NFT5TYpUSU6JRWK=
NCI-H1355 NXfFOWRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMUixN|Uh|ryP M1zGfnNCVkeHUh?=
G-401 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3TESWlEPTB;MD6xPFI{KM7:TR?= MnH3V2FPT0WU
EW-16 NV\VNHVzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13FUmlEPTB;MD6xPFc4PyEQvF2= NGDFVWVUSU6JRWK=
EW-7 M2jPZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfyTGNCUUN3ME2wMlE5QDhzIN88US=> NEXScZdUSU6JRWK=
NCI-H727 NGmxb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TMUWlEPTB;MD6xPVc6PCEQvF2= MVTTRW5ITVJ?
LCLC-97TM1 NULkU25uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMkC5OVUh|ryP Ml[zV2FPT0WU
NCI-H650 NV3n[nVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjBSVVKSzVyPUCuNlE{QDRizszN MWrTRW5ITVJ?
NCI-H2122 Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXMWGZKSzVyPUCuNlMzQTlizszN MVjTRW5ITVJ?
SK-N-DZ MlvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHO[GFjUUN3ME2wMlI{Pjl6IN88US=> M{DsVXNCVkeHUh?=
HT-29 NV[3SJFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\oVGlEPTB;MD6yOFI1QCEQvF2= MUHTRW5ITVJ?
LB771-HNC NYHQbIg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLXTWM2OD1yLkK1PVE2KM7:TR?= NWqyfHBxW0GQR1XS
HT-144 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33IcGlEPTB;MD6yOlE6OSEQvF2= M2DK[XNCVkeHUh?=
LAN-6 NHjWO5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfCZ4xKSzVyPUCuNlY{PDhizszN NWLyTpJzW0GQR1XS
EW-18 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LKR2lEPTB;MD6yO|AxOSEQvF2= NGLRXFhUSU6JRWK=
LS-1034 Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfDbYlKSzVyPUCuNlcyOzJizszN MUTTRW5ITVJ?
EW-11 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwMki0N|Ih|ryP NGjsepVUSU6JRWK=
SNU-C1 NFPufYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLBbZNCUUN3ME2wMlI6OzF|IN88US=> M{m3NnNCVkeHUh?=
RS4-11 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwM{O3OVgh|ryP NInOTVNUSU6JRWK=
ES4 NW\YZ|ZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\Ub2lEPTB;MD60NVA{QCEQvF2= M2rXfXNCVkeHUh?=
COLO-320-HSR NUfyPHY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnGTWJKSzVyPUCuOFE{PjhizszN NEHsT5VUSU6JRWK=
NB10 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;sTWM2OD1yLkS1OFM4KM7:TR?= NUK2VZR{W0GQR1XS
BFTC-905 Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nIdmlEPTB;MD60Olc2QCEQvF2= NInheGxUSU6JRWK=
A375 M1f6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\YTpRkUUN3ME2wMlQ4PjF5IN88US=> NFSxVVNUSU6JRWK=
SJRH30 NXzkS2JMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;FTWM2OD1yLkWwPFIzKM7:TR?= MXrTRW5ITVJ?
NOS-1 M1XoT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILh[GhKSzVyPUCuOVIzPjdizszN MX\TRW5ITVJ?
SIG-M5 NH;6OnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPXTWM2OD1yLkWzOVU4KM7:TR?= NXz1SYhMW0GQR1XS
DOK NXS2TYM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofGTWM2OD1yLkW1OkDPxE1? NWnjcGV6W0GQR1XS
NB69 M1;2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr2SIlKSzVyPUCuOVgzPTdizszN MkLyV2FPT0WU
SK-NEP-1 NIjsVJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHYdYhKSzVyPUCuOlAzOzZizszN MYTTRW5ITVJ?
SK-MM-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2frW2lEPTB;MD62OVQ6OSEQvF2= NX;ZO|NDW0GQR1XS
NCI-H358 M2DMd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwNkewPFIh|ryP MVjTRW5ITVJ?
RH-1 MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHqTWM2OD1yLke0PFU6KM7:TR?= Mmj2V2FPT0WU
NH-12 MmrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfFTWM2OD1yLke2NFQ3KM7:TR?= NXTkXmNjW0GQR1XS
TE-12 NVXjPI92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zWWmlEPTB;MD63OlQ5PiEQvF2= M4ew[3NCVkeHUh?=
COLO-668 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwOES2OlYh|ryP MV;TRW5ITVJ?
PANC-08-13 NU\XZmN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwOE[zO|ch|ryP M2X1[HNCVkeHUh?=
HCC2998 NWTHWnA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTtN49KSzVyPUCuPFgzPjNizszN M4q2cXNCVkeHUh?=
ABC-1 NXfuZnVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDzNJNKSzVyPUCuPVA{PTJizszN NV:0XYs{W0GQR1XS
ES6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwOUGwOlYh|ryP Mlr6V2FPT0WU
SNU-387 NF33fGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXFTWM2OD1yLkm5N|k{KM7:TR?= MlTpV2FPT0WU
CMK NG\6THRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSxXGNKSzVyPUCuPVk6OjlizszN NFW4co1USU6JRWK=
SJSA-1 NEe5WFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTIbG5mUUN3ME2xMlA{PjV|IN88US=> NHSzNpFUSU6JRWK=
SIMA MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfRTWM2OD1zLkC2PFI2KM7:TR?= NFfWT4JUSU6JRWK=
ES3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;veGlEPTB;MT6xNlI6PyEQvF2= M4nG[3NCVkeHUh?=
IGROV-1 Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D3eGlEPTB;MT6xOVQ1PCEQvF2= NVTUdFlFW0GQR1XS
MEL-JUSO NUS2NW1ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jpRmlEPTB;MT6xOVc2QSEQvF2= MkKzV2FPT0WU
T84 MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zmfGlEPTB;MT6yNFkyPCEQvF2= Ml\wV2FPT0WU
CAL-85-1 MnLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHDOGw4UUN3ME2xMlI{OTN6IN88US=> NVLNSIVQW0GQR1XS
RD NFfT[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTFwMk[0OVUh|ryP NVKw[pJWW0GQR1XS
TE-8 NVnTWVh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\ITWM2OD1zLkOxOFYzKM7:TR?= Ml71V2FPT0WU
L-363 NWnTUWQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\yTWM2OD1zLkO0NlA5KM7:TR?= NF7QXZFUSU6JRWK=
EKVX NV3kXW51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLqTWM2OD1zLkO0OVY5KM7:TR?= NF;pWFhUSU6JRWK=
SK-MEL-3 Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHHSVhKSzVyPUGuOFg2PTZizszN NI\nfI1USU6JRWK=
TGBC24TKB NHTK[pNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLTTWM2OD1zLkWwNVk{KM7:TR?= NGC0NpdUSU6JRWK=
NCI-H1770 MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jaW2lEPTB;MT61NVEyOyEQvF2= NGXVc4dUSU6JRWK=
HuH-7 NYTpNGdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPJTWM2OD1zLk[wNFk5KM7:TR?= MlTmV2FPT0WU
HL-60 NFfjW5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr5TWM2OD1zLk[2PVI5KM7:TR?= NIrqVYlUSU6JRWK=
TE-1 M3vVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX30SpNoUUN3ME2xMlcxQTR3IN88US=> MVnTRW5ITVJ?
LC-2-ad NETCZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD0OlhrUUN3ME2xMlc{QDh5IN88US=> MXPTRW5ITVJ?
LB647-SCLC MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3oW|dKSzVyPUGuO|Y2QDNizszN MUDTRW5ITVJ?
NCI-H2171 M{LybGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrRTItKSzVyPUGuO|c4OTZizszN NI\VU5NUSU6JRWK=
SK-PN-DW NXTMbnNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwOUGyPVgh|ryP NXe2RpJwW0GQR1XS
MC-IXC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGj1XVBKSzVyPUGuPVg6QCEQvF2= M3nUWHNCVkeHUh?=
LS-513 M172XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJwMEWzNFUh|ryP NIHsSYlUSU6JRWK=
EW-3 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe4N5pJUUN3ME2yMlA6QDR2IN88US=> NEnuVoNUSU6JRWK=
OPM-2 Ml[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJwMUCyJO69VQ>? NGfCVZRUSU6JRWK=
LP-1 Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL5SWVKSzVyPUKuNlU5ODdizszN NE[5OY9USU6JRWK=
LU-134-A NGn4V4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJwMke3JO69VQ>? MXjTRW5ITVJ?
CP66-MEL MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6xNWtKSzVyPUKuNlkxOTRizszN MkK5V2FPT0WU
HCC1143 NILoU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvnN5dGUUN3ME2yMlQ2OzZ6IN88US=> MVvTRW5ITVJ?
LOXIMVI M3jNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LzNGlEPTB;Mj62NFIyKM7:TR?= NYLIdIoxW0GQR1XS
TE-10 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXYfWhKSzVyPUKuO|A5OzhizszN NV3ORlRJW0GQR1XS
NCI-H1882 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYf5OllkUUN3ME2yMlc2OjJ5IN88US=> NUTTT25iW0GQR1XS
CHP-126 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3GTWM2OD1{Lke2N|E4KM7:TR?= M2r3S3NCVkeHUh?=
NCI-H1623 M{fSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;CcGlEPTB;Mj65NlAzPCEQvF2= NVLobJZsW0GQR1XS
GB-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H1Z2lEPTB;Mj65N|QxPCEQvF2= MnrDV2FPT0WU
RCC10RGB NWPPTlM3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvqTWM2OD1{Lkm1NlgyKM7:TR?= NGjoZpFUSU6JRWK=
NCI-H2141 NXrTVYtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn:3TWM2OD1{Lkm2PFk3KM7:TR?= NUi5Zoh3W0GQR1XS
GI-ME-N M3jkbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPwbJNEUUN3ME2zMlAxPTZ3IN88US=> NIjBWnJUSU6JRWK=
NCI-H526 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTNwMESwPFUh|ryP MmnEV2FPT0WU
NCI-H747 M2LKOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DDXGlEPTB;Mz6wOFk6OiEQvF2= M4DEd3NCVkeHUh?=
SNU-423 M1PGZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTNwMkCzNVMh|ryP NFHDNY1USU6JRWK=
A427 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrSTWM2OD1|LkK1Olk6KM7:TR?= NH63XopUSU6JRWK=
CAL-12T MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e2U2lEPTB;Mz60NFcyOyEQvF2= Mn62V2FPT0WU
LU-99A NHrhPW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MomxTWM2OD1|LkS3NVA2KM7:TR?= Mkf2V2FPT0WU
MS-1 MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjXfIhPUUN3ME2zMlU{PDJ7IN88US=> MVvTRW5ITVJ?
SK-LU-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvzSHJ{UUN3ME2zMlc3Ojl3IN88US=> MkDuV2FPT0WU
SW837 MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf2flZKSzVyPUOuO|Y{OzNizszN M2fOc3NCVkeHUh?=
ES8 M1Hkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTNwOEO4O|ch|ryP NWfW[XRNW0GQR1XS
MZ2-MEL MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXToV|lzUUN3ME2zMlkzODh4IN88US=> MnzkV2FPT0WU
TGW NYKzT|RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXJbFNDUUN3ME20MlAyOzFzIN88US=> NIn3bW5USU6JRWK=
GP5d M161Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTRwMEWzOlIh|ryP NEjmXFFUSU6JRWK=
BB49-HNC Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fjT2lEPTB;ND6xOVIyOyEQvF2= NETNN3JUSU6JRWK=
NB13 NGP0TFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnjN2U3UUN3ME20MlI3QDh5IN88US=> MlrlV2FPT0WU
NTERA-S-cl-D1 NXzLb21QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXQS3JsUUN3ME20MlI5PjF3IN88US=> M4G1enNCVkeHUh?=
NCI-H1648 M2T6V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\wTWM2OD12LkK5PFE6KM7:TR?= NHnzXYNUSU6JRWK=
LCLC-103H MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnqwTWM2OD12LkOyNVk2KM7:TR?= MYfTRW5ITVJ?
LS-411N NFL1VlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLQTWM2OD12LkS0PFg2KM7:TR?= M4TBUHNCVkeHUh?=
NCI-H1092 NVXsU4NDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2G0b2lEPTB;ND60OVY5PyEQvF2= M1TacHNCVkeHUh?=
PANC-10-05 MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme0TWM2OD12Lk[5PFQh|ryP Ml7RV2FPT0WU
DK-MG NUDXfZpWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\tN2IzUUN3ME20MlgxQTN|IN88US=> MnHwV2FPT0WU
OVCAR-5 NHfDfIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTRwOEGyNlYh|ryP M1;HS3NCVkeHUh?=
CAL-39 NXfuW3l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnDTWM2OD12Lki3Olch|ryP MVPTRW5ITVJ?
TE-441-T Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDnTWM2OD12LkmwOVM4KM7:TR?= NY\ld3Q4W0GQR1XS
MOLT-16 NImyU|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrwXoVKSzVyPUSuPVUzPTNizszN MmOwV2FPT0WU
MCF7 M{f1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHxdFE3UUN3ME21MlE1PTF5IN88US=> M2rUZnNCVkeHUh?=
CAPAN-1 NVnsN3RuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFX0PFFKSzVyPUWuNlU4ODdizszN NXjvZ2JUW0GQR1XS
PSN1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fYT2lEPTB;NT6yO|I{PSEQvF2= NVzkW4ptW0GQR1XS
NCI-H292 M1v3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7tTWM2OD13LkOwNFQ1KM7:TR?= NI\mTYVUSU6JRWK=
CPC-N NYHRSZZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXrTWM2OD13LkO5OFE6KM7:TR?= NW[ySlNzW0GQR1XS
DoTc2-4510 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnmxTWM2OD13LkS1N|cyKM7:TR?= MXLTRW5ITVJ?
LB1047-RCC NIXSeVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTVwNUW5N|Mh|ryP MnvSV2FPT0WU
MHH-ES-1 NV3Fc2hFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILFfFJKSzVyPUWuOVk6ODdizszN NH7lUFhUSU6JRWK=
NMC-G1 NXTHTYw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;XXZBKSzVyPUWuO|AzOjdizszN M13PWHNCVkeHUh?=
SW1710 MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rSR2lEPTB;NT63OFc2OSEQvF2= NFW1V5JUSU6JRWK=
YAPC MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTVwN{[yNFEh|ryP NH;iTlFUSU6JRWK=
22RV1 NFzxR|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M330[mlEPTB;NT64NFAyQSEQvF2= MUDTRW5ITVJ?
COLO-679 MnztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz5VHNXUUN3ME21Mlg5QTR6IN88US=> MoH5V2FPT0WU
TCCSUP MoTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnDSYJFUUN3ME21Mlk{OjV7IN88US=> NIT5RphUSU6JRWK=
C2BBe1 MkDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTVwOUO5O{DPxE1? NGK2OpRUSU6JRWK=
TE-15 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj6fFdbUUN3ME22MlA3PjB3IN88US=> MYHTRW5ITVJ?
SCLC-21H MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLCd5h4UUN3ME22MlExQDR|IN88US=> NET1N3VUSU6JRWK=
EoL-1-cell NVjRfJR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{CyS2lEPTB;Nj6xOlU3OyEQvF2= NWjESWVKW0GQR1XS
NKM-1 M{f1Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XnbWlEPTB;Nj6xOlcyKM7:TR?= M{T1TXNCVkeHUh?=
NCI-H1304 MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3z4NWlEPTB;Nj6yO|QzQCEQvF2= M1nNOHNCVkeHUh?=
NB6 NF;wPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTZwMkm2NlIh|ryP M{TTVXNCVkeHUh?=
NALM-6 NYLhcY1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPPcHFKSzVyPU[uN|MzOyEQvF2= MorVV2FPT0WU
NCI-H522 M{L6VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTZwM{OzNFYh|ryP MU\TRW5ITVJ?
MV-4-11 NVXvdmhvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrLPZk2UUN3ME22MlM4ODd7IN88US=> M1r5bXNCVkeHUh?=
LB2241-RCC M2HFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XRSmlEPTB;Nj6zPFY3PyEQvF2= NIrBd49USU6JRWK=
NCI-H1417 NIjhZo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DCSWlEPTB;Nj60NFg1PyEQvF2= NHrDNYVUSU6JRWK=
HT-1197 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm3XXlKSzVyPU[uOVcyOjJizszN NGPucnVUSU6JRWK=
P30-OHK NWHBPIpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\u[2E4UUN3ME22MlYzPzdizszN NV\0VY1kW0GQR1XS
ALL-PO MmrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTZwN{G5NVYh|ryP MV7TRW5ITVJ?
OVCAR-4 NIjvTJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTZwN{W0NFUh|ryP MlfCV2FPT0WU
HCC2157 NWD3PJZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTZwN{e0O|Uh|ryP NYHCdHJRW0GQR1XS
NCI-H838 MkHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmixTWM2OD14Lkm2OFkh|ryP NHLGXI5USU6JRWK=
NCI-H1299 M4HVSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTZwOUewPUDPxE1? Ml\jV2FPT0WU
SW954 NXziTYtpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LLbGlEPTB;Nz6yNFA3QCEQvF2= NGHO[VVUSU6JRWK=
NCI-H441 NEn3N25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTuXWtRUUN3ME23MlM1ODZ3IN88US=> M{HS[3NCVkeHUh?=
SK-MEL-2 M3i1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILuTY1KSzVyPUeuOFg{PzNizszN MUjTRW5ITVJ?
KARPAS-45 NGDGc4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTdwNkW5Nlkh|ryP MmexV2FPT0WU
CAL-54 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnBfXpqUUN3ME23MlgzQTd5IN88US=> MW\TRW5ITVJ?
KYSE-180 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHZOnN3UUN3ME23Mlg5QTRzIN88US=> MnPYV2FPT0WU
NCI-H187 M2PQSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlv2TWM2OD15Lkm1PVQ4KM7:TR?= NFrVXphUSU6JRWK=
RT-112 NHj1W4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\0[2lEPTB;OD6wPVY4PyEQvF2= M3PkSHNCVkeHUh?=
NCI-H1437 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXu0PVJJUUN3ME24MlA6Pzl3IN88US=> MnPOV2FPT0WU
SNU-449 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2m2cmlEPTB;OD6yPFI4OiEQvF2= MWLTRW5ITVJ?
HCC1187 NGnpNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRThwMkmzPVEh|ryP MnzJV2FPT0WU
NCI-H2030 Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjYUoxZUUN3ME24MlM4PzF2IN88US=> NVzCXJdxW0GQR1XS
HuO-3N1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[3R2lEPTB;OD6zO|g1PCEQvF2= NF64Z3RUSU6JRWK=
COLO-792 NIXwS|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTGTnNOUUN3ME24MlQyPTJ5IN88US=> NF3CbmtUSU6JRWK=
MIA-PaCa-2 M4PwUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRThwOEW1NFgh|ryP MXHTRW5ITVJ?
SK-N-FI NH;Qb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH21eXBKSzVyPUmuNFQzPSEQvF2= M1;ZbXNCVkeHUh?=
MMAC-SF NGfYe3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEH0cJVKSzVyPUmuNFk4PTFizszN MUjTRW5ITVJ?
NCI-H28 NX3LW4NTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz2V3FKSzVyPUmuNVA1PjlizszN MUTTRW5ITVJ?
ETK-1 NHfrSHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLyNYxKSzVyPUmuNlk6PzRizszN NFnL[2lUSU6JRWK=
NCI-H1993 M1fieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDXTWM2OD17LkS0NlYyKM7:TR?= M17RZ3NCVkeHUh?=
no-11 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnTTWM2OD17LkS3NVIh|ryP NYLQO2VDW0GQR1XS
ChaGo-K-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XaXWlEPTB;OT61NVU5OyEQvF2= M2jqNHNCVkeHUh?=
NCCIT MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XMZmlEPTB;OT61N|E3QSEQvF2= MUfTRW5ITVJ?
SAS NVfVOog4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Tu[GlEPTB;MUCuNlQ5KM7:TR?= MmniV2FPT0WU
A673 NV;FNHo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HrZWlEPTB;MUCuN|cxPCEQvF2= M3\FRnNCVkeHUh?=
NCI-H1522 MkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrsTWM2OD1zMD6zO|A4KM7:TR?= NVzOdG1LW0GQR1XS
NCI-H810 NWrqRW97T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFyLkO5NFch|ryP NHTNS3BUSU6JRWK=
IST-MES1 NV3VWXRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nYV2lEPTB;MUCuOFU3PCEQvF2= NXiwd3djW0GQR1XS
GR-ST NFnWSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLEZ4JKSzVyPUGwMlUxOjRizszN MVHTRW5ITVJ?
SUP-T1 Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\YfWNKSzVyPUGwMlc{OTdizszN NIX2U5ZUSU6JRWK=
NB5 NGKzVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jQemlEPTB;MUCuPVAzOiEQvF2= M1fuRXNCVkeHUh?=
MZ1-PC NH\GU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnIWGVKSzVyPUGwMlk2PzFizszN MYLTRW5ITVJ?
SK-CO-1 M{nXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2S0UmlEPTB;MUCuPVk{OSEQvF2= M2rGd3NCVkeHUh?=
Capan-2 M2j6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PFU2lEPTB;MUGuN|E6QCEQvF2= NV7BS5ZFW0GQR1XS
697 NXLUUnJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL1TY9zUUN3ME2xNU43PzV5IN88US=> NHWzZoNUSU6JRWK=
REH NYrRU4M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoSxTWM2OD1zMT63OFUyKM7:TR?= M3jDZnNCVkeHUh?=
GI-1 NWjh[YUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXwTWlKSzVyPUGxMlg3OTVizszN MYrTRW5ITVJ?
BB65-RCC M2PIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTF{LkC5NVYh|ryP NWjvVVVJW0GQR1XS
NCI-H1651 MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPZTWM2OD1zMj6yOFc5KM7:TR?= MnjIV2FPT0WU
NCI-H1618 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF{LkO5O|Yh|ryP NX3wRmJ4W0GQR1XS
NCI-H2081 M2Lpdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPQSYgzUUN3ME2xNk43OTRzIN88US=> Mn\2V2FPT0WU
GCIY MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTJSlRZUUN3ME2xNk44OjF|IN88US=> M4X3e3NCVkeHUh?=
NY NGS1[plIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3WwSmlEPTB;MUOuNFY1OyEQvF2= NXnpRpFYW0GQR1XS
PANC-03-27 M{HYWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3QeJlJUUN3ME2xN{4xQDB5IN88US=> MknUV2FPT0WU
BHY NV;nSG9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF|LkKxNlEh|ryP MXPTRW5ITVJ?
SK-OV-3 NF3tWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvuTY1jUUN3ME2xN{4{PzZ|IN88US=> NF;Jc4NUSU6JRWK=
5637 NVXiVVZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTF|Lke3OVkh|ryP M3e1bXNCVkeHUh?=
LC-1F MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTF2LkCzOVYh|ryP MojUV2FPT0WU
SNB75 NVHWbY1TT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE[3SWJKSzVyPUG0MlA{QDNizszN MoPDV2FPT0WU
CHP-212 Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGW3RZdKSzVyPUG0MlA1PjRizszN M1\VenNCVkeHUh?=
HT-1376 NX7TdI17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLBfIlHUUN3ME2xOE4yOTJ4IN88US=> NXXz[pB[W0GQR1XS
MONO-MAC-6 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3kUYhKSzVyPUG0MlE2ODJizszN NELmNI9USU6JRWK=
CA46 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHrWGFKSzVyPUG0MlE5OjdizszN MYDTRW5ITVJ?
SCC-15 NEjUdmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\GeGlIUUN3ME2xOE42PTh|IN88US=> M1nLNXNCVkeHUh?=
ATN-1 MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPYTWM2OD1zND62OlI4KM7:TR?= MXTTRW5ITVJ?
NCI-H2405 NFjVWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3T3XWlEPTB;MUSuPFE2PyEQvF2= NF30PYpUSU6JRWK=
NCI-H716 NH3mUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PjbmlEPTB;MUSuPFQ6OyEQvF2= NYTVRlVnW0GQR1XS
SW620 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fyb2lEPTB;MUSuPVAyPCEQvF2= M3rHUHNCVkeHUh?=
NCI-H226 NYPkZlBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEmwbIpKSzVyPUG0MlkxQDVizszN M1nHPXNCVkeHUh?=
SW962 Mmm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF2Lkm0N|Ih|ryP M{L3eXNCVkeHUh?=
KYSE-150 Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NES1Vm9KSzVyPUG0Mlk2PSEQvF2= M4LkO3NCVkeHUh?=
OCUB-M M1nDU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7udmdlUUN3ME2xOE46QDh|IN88US=> NV3DSIIyW0GQR1XS
ES7 NFq5R5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\aTWM2OD1zNT6wPVg1KM7:TR?= Ml23V2FPT0WU
SW1463 MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHHcW5KSzVyPUG1MlQzOjNizszN NE\iSWVUSU6JRWK=
CAKI-1 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS0Vmt1UUN3ME2xOU42OzR4IN88US=> MkfEV2FPT0WU
MKN28 NGPlPJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTKTWM2OD1zNT61OFc6KM7:TR?= MWPTRW5ITVJ?
SW13 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HG[2lEPTB;MUWuOlE5KM7:TR?= MUfTRW5ITVJ?
A3-KAW MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTF3Lkm2PVch|ryP NELhO5lUSU6JRWK=
LU-65 NFzwNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfYTWM2OD1zNT65O|Y5KM7:TR?= MVPTRW5ITVJ?
Calu-1 M4flbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT3UZVKSzVyPUG2MlA{PjhizszN NUj1V4ZCW0GQR1XS
ST486 NVvR[IpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\VcHRnUUN3ME2xOk4xPDNzIN88US=> MV;TRW5ITVJ?
BB30-HNC MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF4LkGyOFYh|ryP Mmq3V2FPT0WU
EGI-1 NGC5OIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTF4LkS0OkDPxE1? NH3WPZJUSU6JRWK=
SH-4 NX;FT|hqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{H1emlEPTB;MU[uOFc{OSEQvF2= MoWwV2FPT0WU
MN-60 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1v0VmlEPTB;MUeuNlI6PyEQvF2= Ml;UV2FPT0WU
MPP-89 MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF5LkK0OVkh|ryP MXTTRW5ITVJ?
A2780 M4nJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTF5LkSxN|kh|ryP MmjkV2FPT0WU
Daoy MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jRXGlEPTB;MUeuOFY6PSEQvF2= NETDWVdUSU6JRWK=
NCI-H2126 Mm\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTF5LkS3O|Eh|ryP M1HyW3NCVkeHUh?=
NCI-H1563 NYPRVWFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHq0WHpKSzVyPUG3MlQ6OTdizszN MnrPV2FPT0WU
8-MG-BA MoHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfQfZlvUUN3ME2xO{43PjR6IN88US=> NIrxNXJUSU6JRWK=
786-0 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF5LkizOVMh|ryP NFXyeYpUSU6JRWK=
AM-38 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF5LkmzNFYh|ryP NH\Se|hUSU6JRWK=
COLO-824 M1juN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1KwfmlEPTB;MUiuOFQ{PiEQvF2= M{TFRnNCVkeHUh?=
SK-MEL-30 NVHyOXBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF6LkWwPFIh|ryP M4jW[HNCVkeHUh?=
CESS MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTF6Lke2NFkh|ryP MYHTRW5ITVJ?
BL-70 NF3rdpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTDTWM2OD1zOD64NVU3KM7:TR?= MVzTRW5ITVJ?
NCI-H2170 MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTF6LkmxO|kh|ryP MWrTRW5ITVJ?
HT-3 M{XUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorjTWM2OD1zOD65PFMh|ryP NYHiUJBKW0GQR1XS
BOKU MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTF7LkCzPFEh|ryP MlXQV2FPT0WU
HPAF-II NYDveWdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTF7LkOwNVUh|ryP MoTLV2FPT0WU
KGN MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7sTWM2OD1zOT60O|Y2KM7:TR?= MYnTRW5ITVJ?
MC-CAR MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPqRVNIUUN3ME2xPU43OzF|IN88US=> MljOV2FPT0WU
BHT-101 NUCyb|BZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvLS3BwUUN3ME2xPU44PzdizszN MlXHV2FPT0WU
SW1783 NXjLcXBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr2TWM2OD1zOT63PFA3KM7:TR?= M3nr[XNCVkeHUh?=
KP-N-YN MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJyLkCyOlIh|ryP NFTReFFUSU6JRWK=
LU-165 M2nuO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTBNJdWUUN3ME2yNE42PTdzIN88US=> NIXOPIlUSU6JRWK=
GOTO MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHPN4VKSzVyPUKwMlY1PTFizszN MV;TRW5ITVJ?
EFM-19 M3\CZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHCTWM2OD1{MT6wO|E3KM7:TR?= MULTRW5ITVJ?
CTV-1 MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfuNpZKSzVyPUKxMlExPTRizszN M1PnXXNCVkeHUh?=
HEL NViybZc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTGZlVKSzVyPUKxMlQzOTZizszN M1npVXNCVkeHUh?=
SNU-C2B MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTuTWM2OD1{MT60NlYh|ryP Ml;TV2FPT0WU
ECC4 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X0cGlEPTB;MkGuO|A4KM7:TR?= M1TXXHNCVkeHUh?=
NEC8 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{O2c2lEPTB;MkGuPFM3QCEQvF2= MYnTRW5ITVJ?
KMOE-2 NXi0RZlqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3KzVmlEPTB;MkGuPFkzOSEQvF2= MXPTRW5ITVJ?
NCI-H524 M2fUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHDU3BKSzVyPUKyMlA5ODhizszN MXzTRW5ITVJ?
WSU-NHL Ml\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJ{LkG1O|ch|ryP Mn[0V2FPT0WU
SF126 NWrXfJQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LKdWlEPTB;MkKuNlQ3QSEQvF2= M2C0U3NCVkeHUh?=
HOP-92 Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfxdolxUUN3ME2yNk4{OTZ5IN88US=> M{LPcHNCVkeHUh?=
CTB-1 MmjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoSyTWM2OD1{Mj60Olc4KM7:TR?= NXu2U2NKW0GQR1XS
KYSE-270 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInYVVhKSzVyPUKyMlk{PTdizszN MWnTRW5ITVJ?
SK-MEL-24 NX3rT|QxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJ|LkG4O{DPxE1? MXXTRW5ITVJ?
Calu-3 NYrsWoVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[2TWM2OD1{Mz6yNVI5KM7:TR?= NV\Uc4VOW0GQR1XS
GAMG M3y5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJ|LkKzOlch|ryP NUXtRnlMW0GQR1XS
SW1573 NIrYdIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLyTWM2OD1{Mz63OFE2KM7:TR?= M{XF[3NCVkeHUh?=
MHH-NB-11 NUfQWmpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXETWM2OD1{ND6wNVk1KM7:TR?= Mni0V2FPT0WU
TK10 MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJ2LkWwNVMh|ryP Mk\4V2FPT0WU
LB373-MEL-D MmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUT4O5FzUUN3ME2yOE43ODZ2IN88US=> M1LDTXNCVkeHUh?=
KALS-1 M{DMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTJ2LkezNlch|ryP NFXjUJBUSU6JRWK=
HUTU-80 M1fIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\ETWM2OD1{NT64NFMzKM7:TR?= MY\TRW5ITVJ?
HuP-T3 NWXaOoNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPzTWM2OD1{Nj6xOlc1KM7:TR?= MYnTRW5ITVJ?
OE19 MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe4WHBPUUN3ME2yOk4zOTV|IN88US=> NXLFZmpuW0GQR1XS
J82 M{LwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPacYFKSzVyPUK2MlI1PzFizszN MVrTRW5ITVJ?
DU-4475 NXzjd|c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTJ4LkO4NVkh|ryP Mn7QV2FPT0WU
DMS-53 MlXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXucFB2UUN3ME2yOk42OTN6IN88US=> NETK[49USU6JRWK=
COLO-741 NUDGTY5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfRfIVFUUN3ME2yOk45OzR2IN88US=> NFP2S|dUSU6JRWK=
SW48 NVuxVYd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnlTWM2OD1{Nj64PFIh|ryP MYTTRW5ITVJ?
IGR-1 NHPRVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;OU2lEPTB;Mk[uPVM{PCEQvF2= NX;SfYIxW0GQR1XS
639-V M4H1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vSTWlEPTB;MkeuNFI1PSEQvF2= NYjYUVNkW0GQR1XS
LK-2 NF3DNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXTPWNUUUN3ME2yO{41OTRzIN88US=> MlPJV2FPT0WU
NCI-H2347 M3myUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH6yVmFKSzVyPUK3Mlk3QTlizszN NUX6VWRRW0GQR1XS
NCI-H2228 NXS5SmJQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{f0RmlEPTB;MkiuNFkxPSEQvF2= MkfmV2FPT0WU
LS-123 M1jyS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrEcng1UUN3ME2yPE4yOjZ{IN88US=> M3XyZXNCVkeHUh?=
U031 Mm\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13TTGlEPTB;MkiuNlUzKM7:TR?= NVX4bnhKW0GQR1XS
NCI-H1792 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHuwc3JKSzVyPUK4MlQ4OjFizszN M37VXXNCVkeHUh?=
NCI-H2087 MlGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;ZVlRKSzVyPUK4Mlc2PTJizszN NV\GdnFsW0GQR1XS
NCI-H2342 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz1UVFKSzVyPUK5MlUzODhizszN M3XDfnNCVkeHUh?=
SW626 M1HONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDkUWxsUUN3ME2yPU44PTZizszN NGDGPJRUSU6JRWK=
LB2518-MEL MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHXTWM2OD1{OT64NVUh|ryP NYLBUIpvW0GQR1XS
RXF393 NG\ibGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mln3TWM2OD1|MD6wPVUzKM7:TR?= MkTLV2FPT0WU
LC4-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPKdmdKSzVyPUOwMlMxQTJizszN M2LwPXNCVkeHUh?=
NCI-H1694 NGTPXJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV61VXROUUN3ME2zNE43PjJ2IN88US=> NWmyblg4W0GQR1XS
K5 NXXrW2g4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDoc2dKSzVyPUOwMlk4ODJizszN Mk\5V2FPT0WU
HDLM-2 M4LX[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PrVmlEPTB;M{CuPVczPSEQvF2= M4DoeHNCVkeHUh?=
BCPAP M121dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rqOmlEPTB;M{GuPFM4QSEQvF2= M176VnNCVkeHUh?=
BC-3 M{jvO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3SzU2lEPTB;M{KuNVQxOyEQvF2= MlTpV2FPT0WU
LB996-RCC M33TUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PDXmlEPTB;M{KuNlM2QCEQvF2= MWjTRW5ITVJ?
NCI-H2009 Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVO4ZZhjUUN3ME2zNk41QThzIN88US=> MVnTRW5ITVJ?
HTC-C3 MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTN|Lke1NVkh|ryP NEfiXGVUSU6JRWK=
LAMA-84 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTN2LkS0NFch|ryP MULTRW5ITVJ?
CCRF-CEM NEHPS3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXnTWM2OD1|ND61O|E2KM7:TR?= NXfvdYs6W0GQR1XS
AN3-CA M17VVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXST5NKSzVyPUO1MlA2PjhizszN NUf6U4pQW0GQR1XS
NCI-H1734 NH7wOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfwfWlKSzVyPUO1MlI2PjFizszN MWfTRW5ITVJ?
Ca-Ski NEjjRYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1m4UmlEPTB;M{WuOFExOSEQvF2= MWfTRW5ITVJ?
U-266 NWHqW5h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTOUpJKSzVyPUO1MlYyOTRizszN NGP2OJpUSU6JRWK=
SBC-5 NVGzWZAzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof4TWM2OD1|NT63O|gyKM7:TR?= M2C2fHNCVkeHUh?=
GT3TKB MlnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTN5LkGxOUDPxE1? MYrTRW5ITVJ?
MDA-MB-175-VII MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHZWYxCUUN3ME2zO{4zOjR6IN88US=> NEDoWppUSU6JRWK=
PFSK-1 Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7rSJRFUUN3ME2zO{4zPDN3IN88US=> NV34eHJiW0GQR1XS
IMR-5 M13qcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zuc2lEPTB;M{euNlQ5PyEQvF2= MULTRW5ITVJ?
Daudi MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\CZmlEPTB;M{euN|U6PyEQvF2= NXPGfWFTW0GQR1XS
A498 NUjjbVc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXKTWM2OD1|Nz63NlE5KM7:TR?= M4Pu[nNCVkeHUh?=
SCC-4 NGDnbHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PhcWlEPTB;M{euO|g1OyEQvF2= Mke5V2FPT0WU
COLO-680N M{LSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\oUItKSzVyPUO4MlI5QDVizszN M2q0ZXNCVkeHUh?=
SK-MES-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnEUVBPUUN3ME2zPE4{OjF3IN88US=> NELnNJhUSU6JRWK=
SR MmXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTN6LkW0PVUh|ryP NXLSXXJnW0GQR1XS
LNCaP-Clone-FGC NIPLOoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTuOoFuUUN3ME2zPE42PjN5IN88US=> M4\tfHNCVkeHUh?=
SK-HEP-1 NEXvUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETkb|dKSzVyPUO4Mlc5OjJizszN MlPjV2FPT0WU
BPH-1 NHjM[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTN6LkizNlkh|ryP MYfTRW5ITVJ?
NCI-H1755 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LOeWlEPTB;M{muOVgyPyEQvF2= NET6fnZUSU6JRWK=
LXF-289 MoOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfkXnhKSzVyPUO5MlgxQDRizszN NHrUNGJUSU6JRWK=
SW1088 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSzcXR6UUN3ME20NE4zOTB5IN88US=> MWfTRW5ITVJ?
MOLT-4 NYXXRoM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny3TWM2OD12MD6yPVAyKM7:TR?= MlvMV2FPT0WU
AsPC-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XCcGlEPTB;NECuOFU5OyEQvF2= Mm\6V2FPT0WU
HOP-62 M4n3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3juS2lEPTB;NECuOlU3QCEQvF2= MXLTRW5ITVJ?
A172 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTRyLki1NVEh|ryP NXfkdJNIW0GQR1XS
SN12C MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrBe2JKSzVyPUSwMlk{QDVizszN MkPXV2FPT0WU
MDA-MB-231 NIrGWnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4OzSGlEPTB;NECuPVg6QCEQvF2= NVvDUG1GW0GQR1XS
RPMI-2650 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nhN2lEPTB;NEGuNVU6OyEQvF2= MV\TRW5ITVJ?
KYSE-140 M{nnVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\rTWM2OD12MT64NVI{KM7:TR?= MnrrV2FPT0WU
KINGS-1 M4rYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnRbHpKSzVyPUSyMlQ3QTdizszN MWLTRW5ITVJ?
HSC-3 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDHd21GUUN3ME20Nk43PjZzIN88US=> NXjSXYF{W0GQR1XS
PC-14 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTR|LkG4PFIh|ryP NG\NU2lUSU6JRWK=
COR-L105 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYj6NIlNUUN3ME20N{43PTB{IN88US=> MkTvV2FPT0WU
BE-13 NHv1foVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOzbJdpUUN3ME20OE4zOzdzIN88US=> NUDwTGprW0GQR1XS
NCI-H661 M{nRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O3NGlEPTB;NESuNlk2QCEQvF2= M1;Ye3NCVkeHUh?=
IST-MEL1 NXHJNlNwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nPd2lEPTB;NESuN|U6QSEQvF2= NWXL[oc6W0GQR1XS
HCC1806 MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHxeYtKSzVyPUS0MlU5PzNizszN NEHuUpRUSU6JRWK=
COLO-800 NHP2UYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2xbWJDUUN3ME20OE45PDV|IN88US=> MYjTRW5ITVJ?
IST-SL2 MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmH1TWM2OD12NT6xNlQ4KM7:TR?= MnvSV2FPT0WU
8305C NFHBXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TqRmlEPTB;NEWuN|A6KM7:TR?= MVTTRW5ITVJ?
UACC-62 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\1TWM2OD12Nj6yPFc2KM7:TR?= NIT4Z5NUSU6JRWK=
COR-L23 Mn35S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DqdWlEPTB;NEeuNVk6KM7:TR?= MXPTRW5ITVJ?
EFE-184 NIDHVVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfHdnZEUUN3ME20O{4{QDhizszN NVLzPWNOW0GQR1XS
DMS-114 NIrQOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHHSI1pUUN3ME20O{41OTR7IN88US=> NFfRVINUSU6JRWK=
KYSE-520 NUHoRoprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPyR2I5UUN3ME20PE42OzF3IN88US=> MoXQV2FPT0WU
SNG-M MlnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTR7LkSzOEDPxE1? MULTRW5ITVJ?
A2058 NGTtcIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nsb2lEPTB;NEmuOFg5PSEQvF2= M3HN[HNCVkeHUh?=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

体内試験 OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
細胞試験: [1]
+ 展開
  • 細胞株: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • 濃度: 0.02-0.8 μM
  • 反応時間: 3 days
  • 実験の流れ: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • 製剤: 25 mM tartaric acid
  • 投薬量: 25 mg / kg and 75 mg / kg
  • 投与方法: Orally administrated at once-daily oral dose for 14 days
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
30% PEG 400+0.5% Tween 80+5% Propylene glycol
混合させたのち直ちに使用することを推奨します。
30mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 421.49
化学式

C26H23N5O

CAS No. 867160-71-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (g) = 濃度 (mol/L) x 体積 (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development Inc.|Astellas Pharma Inc April 16 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT02546544 Completed Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • 回答:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1Rシグナル伝達経路

IGF-1R Inhibitors with Unique Features

相関IGF-1R製品

Tags: Linsitinib (OSI-906)を買う | Linsitinib (OSI-906) ic50 | Linsitinib (OSI-906)供給者 | Linsitinib (OSI-906)を購入する | Linsitinib (OSI-906)費用 | Linsitinib (OSI-906)生産者 | オーダーLinsitinib (OSI-906) | Linsitinib (OSI-906)化学構造 | Linsitinib (OSI-906)分子量 | Linsitinib (OSI-906)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID